Disclosed are compounds, which are bradykinin antagonists and are useful
to treat diseases or relieve adverse symptoms associated with disease
conditions in mammals mediated by bradykinin. Certain of the compounds
exhibit increased potency and are expected to also exhibit an increased
duration of action.